Warner SL,Carpenter KJ,Bearss DJ. Activators of PKM2 in cancer metabolism[J]. Future Med Chem,2014,6(10):1 167-1 178.
[2]
Parrales A,Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy[J]. Front Oncol,2015,5:288.
[3]
Wong N,Ojo D,Yan J,et al. PKM2 contributes to cancer metabolism[J]. Cancer Lett,2015,356(2PtA):184-191.
[4]
Yang W,Xia Y,Hawke D,et al. PKM2 phosphory-lates histone H3 and promotes gene transcription and tu-morigenesis[J]. Cell,2014,158(5):1 210.
[5]
Cailly T,Dumas N,Millet P,et al. Synthesis and characterization of a iodine-125-labeled pyrrolo[1,2-a]thieno[3,2-e]pyrazine and evaluation as a potential 5-HT4R SPECT tracer[J]. Eur J Med Chem,2010,45(11):5 465-5 467.
[6]
Jiang Y,Wang Y,Wang T,et al. PKM2 phosphory-lates MLC2 and regulates cytokinesis of tumour cells[J]. Nat Commun,2014,5:5 566.
[7]
Jin J,Lin F,Liao S,et al. Effects of SNPs(CYP1B1*2 G355T,CYP1B1*3 C4326G,and CYP2E1*5 G-1293C),smoking,and drinking on susceptibility to la-ryngeal cancer among Han Chinese[J]. PLoS One,2014,9(10):e106580.
[8]
Samatar AA,Poulikakos PI. Targeting RAS-ERK sig-nalling in cancer:promises and challenges[J]. Nat Rev Drug Discov,2014,13(12):928-942.
[9]
Nguyen TT,Hachisuga T,Urabe R,et al. Signifi-cance of p53 expression in background endometrium in endometrial carcinoma[J]. Virchows Arch,2015,466(6):695-702.
[10]
Gaestel M. MAPK-activated protein kinases(MKs):novel insights and challenges[J]. Front Cell Dev Biol,2015,3:88.
[11]
Sun Y,Liu WZ,Liu T,et al. Signaling pathway of MAPK/ERK in cell proliferation,differentiation,mi-gration,senescence and apoptosis[J]. J Recept Signal Transduct Res,2015,35(6):600-604.
[12]
Lito P,Rosen N,Solit DB. Tumor adaptation and re-sistance to RAF inhibitors[J]. Nat Med,2013,19(11):1 401-1 409.
